BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34059856)

  • 1. Fighting against drug-resistant tumors by the inhibition of γ-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.
    Wang L; Liu Z; He S; He S; Wang Y
    J Mater Chem B; 2021 Jun; 9(22):4587-4595. PubMed ID: 34059856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
    Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
    Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrosion-Activated Chemotherapeutic Function of Nanoparticulate Platinum as a Cisplatin Resistance-Overcoming Prodrug with Limited Autophagy Induction.
    Cheng HJ; Wu TH; Chien CT; Tu HW; Cha TS; Lin SY
    Small; 2016 Nov; 12(44):6124-6133. PubMed ID: 27717137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H; Wang X; Gou S
    J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z; Xu Z; Zhu G
    Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
    Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
    J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Nanostructures as Pt(IV) Prodrug Delivery Systems to Combat Chemoresistance.
    Zhong YF; Cheng J; Liu Y; Luo T; Wang Y; Jiang K; Mo F; Song J
    Small; 2020 Sep; 16(38):e2003646. PubMed ID: 32815274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
    Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
    Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
    Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(β-cyclodextrin)/platinum prodrug supramolecular nano system for enhanced cancer therapy: Synthesis and in vivo study.
    Zhang R; You X; Luo M; Zhang X; Fang Y; Huang H; Kang Y; Wu J
    Carbohydr Polym; 2022 Sep; 292():119695. PubMed ID: 35725183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
    Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
    ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.
    Lin YX; Wang Y; An HW; Qi B; Wang J; Wang L; Shi J; Mei L; Wang H
    Nano Lett; 2019 May; 19(5):2968-2978. PubMed ID: 30924343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X; Li L; Pei S; Zhu Q; Chen F
    Pharmazie; 2020 Mar; 75(2):94-101. PubMed ID: 32213241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F; Qin X; Xu G; Gou S; Jin X
    Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers.
    Han Y; Yin W; Li J; Zhao H; Zha Z; Ke W; Wang Y; He C; Ge Z
    J Control Release; 2018 Mar; 273():30-39. PubMed ID: 29371047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A red-light activatable and mitochondrion-targeting Pt
    Li Y; Wang Z; Qi Y; Tang Z; Li X; Huang Y
    Chem Commun (Camb); 2022 Jul; 58(60):8404-8407. PubMed ID: 35796077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
    Jayawardhana AMDS; Stilgenbauer M; Datta P; Qiu Z; Mckenzie S; Wang H; Bowers D; Kurokawa M; Zheng YR
    Chem Commun (Camb); 2020 Sep; 56(73):10706-10709. PubMed ID: 32789350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.